Innoblative Designs, Inc.
Galveston, Texas
What changed
Phase III trial registered: Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection
3mo agoTrial registeredApr 21, 2026Source filing (opens the source filing in a new tab)
Momentum
Momentum 72 out of 100, unchanged since the last recompute.
Accelerating: several high-weight events landed recently.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Phase III
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Peer position
675 pre-ticker oncology companies at Phase III
Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.
Compare seatsA ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
NA registered
Feb 10, 2026Breast Cancer, Breast-conserving Surgery, Breast Cancer - Infiltrating Ductal Carcinoma, ER/PR+Her2neu, Grade I, II, III · RECRUITING · sponsor: Innoblative Designs, Inc. · Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery
ClinicalTrials.gov · NCT07206121 (opens the source filing in a new tab)
- Trial
PHASE3 registered
Jul 29, 2019Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III · ACTIVE_NOT_RECRUITING · sponsor: Alliance for Clinical Trials in Oncology · Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection
ClinicalTrials.gov · NCT03927027 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources